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Abstract
Background. – Multimorbidity is a consequence of both epidemiological and demographic transition. Unlike comorbidity, it currently has no
consensus definition, making it difficult to assess its epidemiological and socioeconomic burden, to organize healthcare services rationally, and to
determine the skills needed for patient self-reliance. The aim of this study is to define the spectrum of multimorbidity and to discuss current
implications for the organization of care.
Methods. – Two independent readers analyzed the literature indexed in PubMed, Embase, CINAHL, and Scopus.
Results. – The bibliographic search conducted on July 16, 2013, retrieved 2287 articles (670 in PubMed, 666 in Embase, 582 in Scopus, and
369 in CINAHL). Of these, 108 articles were retained. Multimorbidity is designated by a variety of terms, none of them being MeSH terms. There is
no single measure of multimorbidity, as this entity is usually studied for its functional or economic impact, rather than its causes. The prevalence
varies considerably, depending on the measure used and the population studied. Factors associated with multimorbidity are age, gender, and
socioeconomic characteristics of the populations studied. Studies evaluating the organization-of-care are inconclusive or insufficient.
Conclusions. – Multimorbidity serves as an avatar for the fundamental, recurrent problems of modern medicine and the organization-of-care.
It may be defined by its causes or its consequences and reflects our concept of both individual health and its collective management. Tools that
would allow a more appropriate measurement of this entity are available; we should use them to match medical reality to the needs of patients.
# 2014 Elsevier Masson SAS. 
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Re´sume´
Position du proble`me. – La polypathologie chronique est une conse´quence de la double transition e´pide´miologique et de´mographique.
Distincte de la comorbidite´, il n’en existe aujourd’hui aucune de´finition consensuelle, ce qui rend de´licates l’e´valuation de son poids
e´pide´miologique et socio-e´conomique, l’organisation raisonne´e et adapte´e des services de sante´ ou encore la de´termination des compe´tences
ne´cessaires a` l’autonomie des patients. Le but de ce travail est de de´limiter un spectre de la polypathologie chronique et d’en discuter
les implications actuelles quant a` l’organisation des soins.
Me´thodes. – Analyse de la litte´rature re´fe´rence´e par PubMed, Embase, CINAHL et Scopus par deux relecteurs inde´pendants.
Re´sultats. – La recherche bibliographique a permis d’identifier 2287 articles au 16/07/2013 (PubMed : 670, Embase : 666, Scopus : 582,
CINAHL : 369). Au total 108 articles ont e´te´ retenus. La polypathologie chronique est de´signe´e sous diffe´rents termes, dont aucun n’est un terme
MeSH. Il n’existe pas de mesure unique de la polypathologie chronique, cette entite´ e´tant plus souvent e´tudie´e pour ses conse´quences
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facteurs re´currents associe´s a` la polypathologie chronique sont l’aˆge, le sexe et les caracte´ristiques socio-e´conomiques des populations. Les
re´sultats des e´valuations visant l’organisation des soins sont peu concluants ou les e´tudes pre´sentent des insuffisances.
Conclusion. – La polypathologie chronique se pose comme un avatar des proble`mes fondamentaux re´currents de la me´decine moderne et de
l’organisation des soins. Elle pose la question de sa de´finition, a` partir de ses causes ou de ses conse´quences, et renvoie a` notre conception a` la fois
de la sante´ individuelle et de sa gestion collective. Il existe des outils permettant une mesure plus adapte´e de cette entite´, qu’il serait inte´ressant de
mobiliser afin de marier re´alite´ me´dicale et besoins des patients.
# 2014 Elsevier Masson SAS. Tous droits re´serve´s.
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Most countries that have started or completed their
demographic transition are experiencing an epidemiological
transition as well. The growing burden of chronic illness [1,2]
on a country’s healthcare system, social services, and economy
can no longer be ignored [3,4].
The effort to rationalize care and healthcare costs has
produced a plethora of best practice guidelines on specialized
care for the main chronic diseases, established independently
from one another [5], with which specialists to consult and
which tests and investigations to arrange for. This is, however,
an idealized version of reality; chronic diseases rarely occur in
isolation, especially as life expectancy increases and people
acquire a growing number of illnesses [6]. Treating each of a
person’s chronic diseases separately basically sums the
individual costs, which is suboptimal at best. It is therefore
no longer a matter of chronic versus acute disease, but
more likely of multiple chronic diseases, or multimorbidity. At
a minimum, multimorbidity is defined as the co-occurrence
of at least two chronic conditions in the same person.
In a context in which we wish to foster patients’ self-reliance
with respect to their diseases and the healthcare system,
multimorbidity is a challenge. While some recent studies have
attempted to formalize complex interventions, including self-
management support programs [7], the majority of therapeutic
patient education (TPE) programs are designed for a single
disease. As pointed out by d’Ivernois and Gagnayre (2013) [8],
there are currently no operative therapeutic education models
for people with several chronic diseases, given that education
cannot be obtained by adding together different existing
‘‘single-disease’’ programs. We know, for example, how to
educate a diabetic patient, a chronic bronchitis patient, and a
hypertensive patient, but we do not know, in practical terms,
how to educate a patient with all three diseases. The difficulty is
in identifying, out of all of the skills the patient has to master,
which of his various diseases should take priority, and
assembling the educational sequences accordingly.
Numerous studies over the past 20 years have shown that
multimorbidity represents a significant problem, reporting high
prevalence and incidence, high costs and inadequate healthcare
services. Evaluating its importance in terms of public health,
however, remains difficult. The problem, as much for
researchers as for clinicians and patients, is further complicated
by the fact that the concept of multimorbidity probably differs
from the concept of comorbidity. Following Feinstein [9], vanden Akker et al. [10] suggest keeping the term ‘‘comorbidity’’
when talking about a disease of interest – or ‘‘index disease’’ –
for which there are coexisting conditions that are not
necessarily complications of the index disease, called
comorbidities. Multimorbidity then designates all situations
in which several conditions coexist, but none of them takes
precedence over the others – that is, situations in which there
is no index disease. Researchers are still divided as to the
conceptual differences between multimorbidity and comorbi-
dity, and it is not at all rare – especially in the United States – to
see comorbidity used when talking about multimorbidity.
Given the variety of approaches and results dealing with
comorbidity and multimorbidity, as reported in the literature,
we sought to answer the following question: what do we
currently mean by ‘‘multimorbidity’’? Defining the boundaries
of a nosological entity that has no unambiguous definition
involves documenting not just the measures (i.e. the practical
and operational definitions) used to approach it, but also the
related available epidemiological data and the factors
frequently identified as being associated with it. We decided
to look at the literature indexed in various medical databases in
order to try to answer this question. Based on the information
obtained, we also propose to discuss the current organization-
of-care issues relating to multimorbidity.
2. Methods
Our methodology is based on a study by Vogeli et al. (2007
[11]), presented as a semi-structured literature review
consisting in a two-step bibliographic search: an initial search
targeting the heart of the subject (for Vogeli, articles identified
in PubMed with the MeSH terms ‘‘chronic diseases’’ and
‘‘comorbidity’’), and then a second search based on the articles
identified in the first step, this time targeting more specific
characteristics (for Vogeli, for example: prevalence, access to
care, mortality rate, and healthcare expenditures).
In order to collect material for analysis, we did a primary
search on the PubMed database on July 16, 2013, using the
following search string: ‘‘multipathology’’ [Title/Abstract] or
‘‘pluripathology’’ [Title/Abstract] or ‘‘multiple chronic condi-
tions’’ [Title/Abstract] or ‘‘multimorbidity’’ [Title/Abstract] or
‘‘polymorbidity’’ [Title/Abstract]. From this first set we kept
articles written completely in English, but not those in which
only the abstract was in English, to ensure a uniform level of
comprehension of the articles.
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literature search in three other databases – Embase, CINAHL,
and Scopus – using the same search criteria. The aim of the
second search was basically to verify whether the results
found in PubMed were representative of the problem, and if
not, to fill in any references missing from the first selection.
Note that, to the best of our knowledge, there are currently no
MeSH terms dedicated to multiple chronic conditions. In
addition, we tested the same search string with the prefix
‘‘comorbid*’’ added.
We applied secondary criteria to choose articles for a full
reading, to cover the following four areas: the definitions of,
or if lacking, the measures used to identify people with,
multimorbidity; the epidemiological data regarding multi-
morbidity (prevalence and determinants); the factors asso-
ciated with it (mortality, functional capacity, and quality of
life); and the organization-of-care targeting multimorbidity.
Articles that did not explicitly mention those aspects were
rejected. Lastly, we gave priority to systematic reviews
involving one of the areas above. The method is summarized
in Fig. 1.
Two readers read the abstracts from the first selection and
independently performed a second selection using the
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Fig. 1. Selection procedure for articlwas designated to intervene to decide whether or not to include
the article.
3. Results and discussion
3.1. Articles identified
The search string retrieved 2287 articles from PubMed
(670), Embase (666), CINAHL (369), and Scopus (582) on
July 16, 2013. There were 1011 remaining articles after
duplicates were removed (46.6% recovery rate). Adding (OR
‘‘comorbid’’) that same date retrieved 22,465 results from
PubMed alone.
The initial selection ultimately yielded 200 eligible articles
from PubMed, 20 from Embase, 17 from CINAHL, and 13 from
Scopus, for a total of 250 articles (Fig. 1). The articles rejected
at that stage did not actually mention multimorbidity explicitly,
or referred only to comorbidity, despite the form of the search
string.
Of those 250 articles, 108 were read in their entirety,
including eight systematic reviews, all of them indexed in
PubMed. There were no significant disagreements between
the readers necessitating the third reader’s intervention.ching 
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There have been numerous studies on multimorbidity in the
past 20 or so years, and a comprehensive review of the issue via
a literature analysis seemed necessary. While our study
attempted to do this, it has certain limitations.
Our decision not to consider studies on comorbidity may
have cost us some original results. However, we believe that the
concept of comorbidity is either included in the broader concept
of multimorbidity (and most of the comorbidity studies would
only have contributed to more specific and detailed results
than those we cite) or is a totally different concept than that
of multimorbidity, in which case the comorbidity studies did
not belong in this analysis.
In addition, there is gray literature regarding choices in
health policy orientation and the organization-of-care in various
countries that is difficult to use, due to the general nature of the
proposals and their lack of practical evaluation or implementa-
tion. Moreover, most of the references cited in that type of
document were found in our own search. We may also have
misread articles that were not written in English. That risk,
however, is negligible, given the very small percentage of
articles found on the subject that were written in a language
other than English.
While very similar to the 2007 study by Vogeli et al. [11], our
study is not equivalent to theirs. Vogeli et al. attempted to define
the boundaries of multimorbidity, but considered only some of
the terms used to designate it or primarily studies of
comorbidity, thus making no distinction between the two
concepts. In addition, the number of articles found by the
authors seems low to us (623, including the comorbidity
articles). While the decision to consider ‘‘core journals’’ is
acceptable, we find it limiting. Lastly, several systematic
reviews have been published in the seven years since that study,
justifying a new analysis.
3.3. The different measures of multimorbidity
Among the studies included (comorbidities excluded), the
instances of different terms varied; ‘‘multimorbidity’’ or
‘‘multimorbid*’’ and ‘‘multiple chronic illnesses’’ or ‘‘multiple
chronic conditions’’ were the terms used most frequently in our
selection.
We listed four major measures of multimorbidity:
 simply counting the number of chronic conditions from a list
of individual conditions, with the list sometimes varying from
one study to another (rheumatologic conditions such as
osteoarthritis or arthritis might not, for example, be on the
list);
 grouping chronic diseases, which are also chosen from a list
that varies between studies, by dyads or triads;
 using an index of variable complexity based, for example, on
risk or on past healthcare utilization identified as associated
with substantial future care;
 identifying homogeneous groups of people with common
diseases and characteristics.Some of these approaches may use the same classification
techniques but have different objectives; for example, an index
may be constructed based on the same techniques as those used
to identify homogeneous groups. An index of this type,
however, is generally constructed in connection with a
particular patient characteristic, such as healthcare utilization
or premature death. The aim or intention governing the use of
one type of measure rather than another thus determines the
type of measure chosen more than the technique used to
construct it. Two studies, by Huntley et al. (2012) and
Diederichs et al. (2011) [12,13], examined the different
measures used for research. A third study by Le Reste et al.
(2013) [14] recently attempted to propose a definition of
multimorbidity at the primary care level, based on a systematic
review. Rather than finding a single consensus measure, the
authors listed the constitutive dimensions of multimorbidity
(i.e., having at least one other disease in addition to an index
chronic disease, or a so-called biopsychosocial factor, or a
somatic risk factor) and the factors modulating the effects of
the multimorbidity on health (e.g., coping strategies, social
network, or other somatic risk factors). Hence, rather than a
synthesis, it is an analysis of the candidate dimensions for
measuring multimorbidity, or an attempt to characterize the
different possible care situations.
The study by Huntley et al. [12] counted 17 different
measures in 194 primary care studies, including a simple count
of conditions but excluding analyses of homogeneous groups
[12]. More than half of the studies (98/194) used simple
counting. The performance of these measures varied depending
on the assumed consequence of multimorbidity to which they
were assumed to be related: quality of life, mortality, or
functional capacity.
A strong trend seems to exist that measures chronic
multiple diseases in a patient by simply adding up chronic
diseases, selected in lists of diseases that differ from one
author to another. Other more or less complex means of
measuring this phenomenon have been proposed, but none
has met with consensus. While counting is a simple, naı¨ve,
and possibly pertinent way to qualify multimorbidity,
it automatically deprives it of any possible nosological
independence [6]. Identification by common dyads or triads
is a pragmatic compromise, recognizing the epidemiological
particularities of certain multimorbidities, while remaining
simple, but it leaves out others that, while fewer in number,
are not necessarily less important [15]. Indices, which are
generally constructed with the idea of predicting one type
of impact, thus define multimorbidity in a way that
prioritizes a single type of presumed impact [16,17]. Lastly,
the homogeneous groups approach prioritizes adherence to
specific epidemiological features, extends the identification
spectrum to non-biomedical characteristics, and permits
preliminary exploration to find a common pathophysiological
basis for multimorbidity and a common set of skills
required by such patients [18]. Disease counting seems to
be the default identification method of choice, due to its
ease of use.
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by its consequences or its causes was posed some 15 years ago,
but does not yet appear to have been satisfactorily answered
[19,20]. Van den Akker et al. (1996) [10] questioned whether
using the concept of multimorbidity – as distinct from
comorbidity – was necessary. They suggested reserving the
term ‘‘comorbidity’’ to designate so-called index diseases,
coexisting with other conditions such as complications of
the index disease or conditions whose treatment has led to
complications (iatrogenic conditions). They suggest using
‘‘multimorbidity’’ when a person suffers from several
conditions. However, that suggestion conflicts with the fact
that simply counting diseases does not appear to be sufficient,
and that incorporating non-biomedical dimensions such as
self-efficacy, financial constraints, and related or concomitant
functional limitations [21] might be useful. Clearly, the choice
of which measure to use matters, because it influences our
representation of the condition and its epidemiology [17].
In fact, the problem of measuring multimorbidity and of its
definition may be inherited from more primitive causes. On one
hand, if multimorbidity deals with the co-existence of multiple
chronic conditions in one person, one should ask if the concept
of chronic condition is as clear as it seems. A chronic condition
or disease asks the question of the duration of this condition,
which was very likely to be defined in contrast to acute
conditions. For a long time, acute conditions were the rule for
many people, since many non-acute conditions are associated
with aging. Beyond the issue of duration, there is still the
problem of the exhaustive and consensual list of conditions that
everyone recognizes as being chronic conditions.
We could also add to these issues the fact that chronicity can
sometimes be confounded with severity, or even other concepts
such as handicap, deficiency, or quality of life. Finally, when
it comes to the concept of multimorbidity, one could also
wonder if only chronic conditions should be considered or if
acute or transient conditions should be incorporated.
3.4. Epidemiological data concerning the concept of
multimorbidity
One of the first things we might be tempted to ask about the
importance of multimorbidity would be how many people have
it – that is, its prevalence. The use of different measures ofTable 1
Examples of multimorbidity prevalence, by measurement method and study popul
Prevalence (%) Measure Population 
14 Disease counta 99,997 British adults seen by g
56 Index (ACG)
23.2 Disease counta 1,751,841 Scottish patients see
71.2 Disease count 28 million American adults ad
24.5 Disease count 198,670 Spanish patients (age 
29.7 Disease count 60,857 Dutch patients seen by 
37.1 Index (CIRS) 3398 Australian adults seen by
19.3 Disease count 13,806 Dutch patients (age > 1
a Rheumatologic conditions excluded. ACG: Johns Hopkins University adjusted cl
sample.multimorbidity leads to quantitative differences among pre-
valence studies, independent of the subpopulation being
considered. A systematic review on prevalence revealed even
larger differences, depending on the population in question:
from 3.5% to 98.5% in people over 75 years of age, and from
13.1% to 71.8% in the general population [22]. The prevalence
varies not only with the type of measure, but also with the
category of multimorbidity; in the case of disease counts,
prevalence varies depending on whether the criterion used is
two, three, or more conditions. It has been suggested that the
prevalence increases with the number of candidate diseases
[20]. A large number of studies also concern the elderly
[23–26], under the assumption that there is a strong link
between multimorbidity and aging. A sample of the different
prevalence found is shown in Table 1.
The main entities found, by the measure used, are shown in
Table 2. The particular position of mental health should be
noted; if the problem appears to be recognized by the
psychiatric profession [27], the approach is significantly
different. It is usually a question of improving psychiatric
patients’ physical care, or measuring the impact of their mental
illness on their physical ailment [28–30]. One study, however,
pointed out that the likelihood of a mental disorder being
among the multiple morbidities increased with the number
of physical disorders in a given person, and that the prevalence
of a psychiatric component increased significantly with the
degree of deprivation [6].
Whatever the measure used, there are basically three factors
repeatedly associated with multimorbidity: age, gender, and
socioeconomic status. While age might be expected, multi-
morbidity should not be understood solely as the effect of
aging; it does occur in specific young or middle-aged groups, in
people with endocrine disorders (for example, see [18]). In fact,
in absolute terms, more young than elderly (i.e. over age 65)
people were found to have multimorbidity [6]. All of the studies
that looked at the impact of socioeconomic status concluded
that there was a higher prevalence of multimorbidity among the
poor, with possible qualitative differences (for example, a
higher prevalence of mental illness appearing as one of the first
pillars of multimorbidity in that population) [6,16]. Ethnicity
also plays a role, with distinct temporal trajectories [31].
Due to the chronic nature of multimorbidity, its estimated
prevalence, and the burden it represents in terms of diminishedation.
Reference
eneral practitioners Salisbury, 2011 [16]
n by general practitioners Barnett, 2012 [6]
mitted to the hospital over 1 year (NIS) Steiner, 2013 [15]
> 14 years) seen by general practitioners Garcia-Olmos, 2012 [18]
general practitioners van den Akker, 1998 [60]
 general practitioners Britt, 2008 [61]
6 years) seen by general practitioners Westert, 2001 [62]
inical groups; CIRS: Cumulative Illness Rating Scale; NIS: nationwide inpatient
Table 2
Examples of large multimorbidity groups by measurement method, comorbidity studies excluded.
Groups Measure Description Reference
4 groups PCA Group A: cardiac arrhythmias, hyperlipidemia, hypertension,
diabetes, age > 70
Group B: ischemic heart disease, cerebrovascular disease, chronic
kidney failure, congestive heart failure, age > 80
Group C: asthma, thyroid disease, anxiety or depressive disorder,
schizophrenia, age < 30
Group D: other conditions (obesity, osteoporosis, deafness,
cancer, etc)
Garcia-Olmos, 2012 [18]
12 dyads Disease count Four most common dyads:
Arthritis + vascular disorder
Psychiatric + vascular disorders
Arthritis + psychiatric disorder
Cardiac + vascular disorders
Britt, 2008 [61]
5 groups FA + index (ACG) Cardiometabolic disorder group
(cross-sectional)
Psychiatric disorder/substance abuse group (young men)
Mechanical disorder/obesity/thyroid disease group (men < 45 years)
Psychogeriatric disorder group (women > 65 years)










PCA: principal component analysis; FA: factor analysis; ACG: Johns Hopkins University adjusted clinical groups.
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have been the subject of specific studies.
However, most of the results fail to provide a precise set
of data.
Most studies agree that there is excess mortality due to
multimorbidity [15]. Some studies, however, suggest that the
higher mortality is associated with disability, rather than
multimorbidity; this was shown in one longitudinal study
following elderly patients [32]. In this study, the degree of
disability was better correlated with excess mortality than was
multimorbidity itself.
The impact of multimorbidity on quality of life is not clear.
Some studies show a worse quality of life overall [33], though
not all aspects of quality of life are inversely related to
multimorbidity (that is, the reduction in quality of life does not
seem to be systematically proportional to the number of
conditions). Social and psychological aspects appear to be
increasingly degraded as the number of conditions rises above
three.
Regarding the quality of care and prevention given
multimorbid patients by caregivers, while not all of the results
agree, there seems to be a trend toward better quality care [34]
and prevention [35] among people with multimorbidity. The
authors attribute better-quality care to more frequent or
redundant contact with the healthcare system, as people are
seen for each condition separately. This is the case, for example,
for people followed for both cardiovascular disease and
diabetes, who may be prescribed testing, advice, and
consultations by each of the specialists (the cardiologist, the
diabetologist and, possibly, the primary care physician).
The quality would therefore not be attributable to synergisticcare or to potentiation of more effectively delivered messages,
but rather to the patient’s higher probability of being seen
by a healthcare professional. But as Langan et al. (2013) [27]
point out, this observation mainly reflects somatic multi-
morbidity, without sufficient consideration for, or focus on,
the psychiatric component. Moreover, it should be noted that
the opportunities for catch-up increase, mainly because the care
model is still focused on the concepts of comorbidity and
biomedical measurements. Also worth noting is that this better
quality does not apply to all types of care; despite their high
prevalence, the literature has little or no discussion of dental
and ophthalmological care.
Similarly, more frequent contact with the healthcare system,
for each separate condition and repeated over time, auto-
matically means higher healthcare utilization – such as more
hospital admissions and outpatient visits – and hence higher
costs [15]. We can also note that one definition of
multimorbidity is based on the risk of high future healthcare
utilization [16]. Conversely, the 2012 Brilleman and Salisbury
study [36] compared the usefulness of different measures of
multimorbidity in terms of the primary outcome to be
measured. It turns out that the number of drugs prescribed
was the best predictor of future outpatient visits, and the
second-best predictor of mortality. However, most of the
indices were good predictors of 3-year mortality.
Another important aspect of the epidemiological approach
of multimorbidity relies on novel and expanding ways to
harvest and analyze personal and population data. The
information and healthcare systems are increasingly developing
in hospitals and many healthcare or health-related databases
are already available (e.g., claims databases).
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d’information (PMSI) is both a medical and administrative
database. The main medical data available in the PMSI are
the primary diagnosis (the primary motive for being in the
hospital at this time) and the secondary or associated diagnoses
(co-occurring diseases or complications of the primary motive,
for example). From this point of view, approaches and measures
of multimorbidity are obviously limited or biased. The structure
and composition of medical databases can thus be an important
obstacle to the development of appropriate or novel approaches
[37,38]. Nonetheless, the integration of data of diverse
types (e.g. social habits or lifestyle) may address these issues.
This is the purpose of so-called big data [39].
Furthermore, considering a particular database, one will
have to address a second type of problem. Novel and
appropriate analysis tools should be used to overcome current
limitations due to classical and reductionist methods [40].
3.5. Multimorbidity-specific treatments and healthcare
system organization
From an organizational point of view, Tinetti et al. (2012)
and Boyd (2005) [41,42] noted the mismatch between the
reality in the field (that chronic disease rarely occurs in
isolation), the narrowly disease-specific nature of treatment and
reimbursement, and best practice guidelines targeting only
single diseases. Compartmentalization by medical and para-
medical specialty leads to the fragmentation of patient care,
resulting in a loss of meaning that is felt by patients; they report
that they do not understand the logic of the system or how it
relates to their own experience. Their care becomes a string of
appointments that fails to offer any clear understanding of the
conditions from which they suffer [26].
Depending on the number of chronic conditions, following
guidelines was considered unworkable, too burdensome, or
even contradictory [5]. An examination of those same
recommendations shows that comorbidities and their specific
features are only rarely mentioned. Moreover, while those
guidelines are recognized as being highly evidence-based
(since they generally came from randomized controlled trials),
there were doubts about the external validity of those trials
when it came to extrapolating their results to multimorbidity,
and due to their artificial nature, since diseases rarely occur
singly [43,44]. For example, the vast majority (from 89% to
100%) of people selected for five clinical trials on hypertension
actually had multiple chronic conditions [44].
Most of the interventions to improve care for people with
multiple conditions for which randomized controlled trials
were conducted were based on modifying the primary care
system to various degrees. Some of the studies looked primarily
at alternative ways of organizing care: having a third party
coordinator (‘‘integrated care manager’’) work with general
practitioners and patients to improve management of comorbid
hypertension and depression [45]; having a pharmacist suggest
more appropriate, synergistic prescriptions in cases of multiple
drug therapy [46]; and having a general practitioner, dedicated
nurse, and social worker work together to reach a better overallunderstanding of the patient’s situation [47]. The other studies
looked more at so-called patient-centered approaches: having
therapeutic patient education by occupational therapists and
physical therapists for better management of the patient’s
cognitive, physical, and environmental resources [48], or
offering workshops to help patients get the most out of their
visits [49].
These interventions were the subject of a Cochrane Library
systematic review, which looked at ten of them [50]. The
studies were heterogeneous in terms of objectives and
intervention methods, had a very moderate impact, and were
difficult to compare. In particular, the Cochrane review stressed
the need to evaluate interventions that work with, or are
integrated into, the healthcare system, to ensure their
sustainability should show positive results. It has also been
suggested that minor adjustments to the existing system – via a
process or pathway set up alongside the usual care for chronic
conditions, for example – would not suffice [51]. The Cochrane
review also pointed out that offering appropriate services
completely divorced from the current systems and infrastruc-
ture without incurring significant costs would be difficult.
We identified six major coordinated management programs
primarily targeting the elderly, and thus their multiple
conditions. Boult and Wieland (2010) [52] compared three
initiatives launched in the United States: Program of All-
inclusive Care for the Elderly (PACE), Geriatric Resources for
Assessment and Care of Elders (GRACE), and Guided Care.
Three other countries have implemented this type of program:
the United Kingdom (Evercare), Canada (SIPA), and the
Netherlands (EASYcare) [51,53,54]. While the studies do not
explicitly or directly target multimorbidity as such (which is
why they were not included in the Cochrane review), they do
offer a controlled evaluation of the organization-of-care for
fragile or at-risk elderly – practically speaking, those with
multimorbidity. Regarding the three U.S. programs, each has
specific limitations, according to Boult and Wieland [52]:
restrictive program eligibility criteria and regional disparities
between dedicated facilities, together with a relatively small
total number of such facilities, which are rapidly approaching
capacity.
The other three initiatives generally show increased patient
satisfaction or well-being of subject groups, with fewer hospital
admissions at costs that are similar and constant overall [53] in
some cases, or no gain in terms of healthcare utilization
(emergency room visits, for example) [51]. Though there may
be a positive short-term impact on functional capacity, it is
moderate and tends to disappear fairly quickly [54].
In addition to the Cochrane review, which looks only at
randomized controlled trials in primary care, the systematic
review by De Bruin et al. (2013) [55] more broadly examines
evaluations of so-called comprehensive care programs aimed
specifically at multimorbidity. This review surveyed 28 pro-
grams evaluated by 33 studies. Its conclusions are similar to
those of the above-cited studies; such programs show a
moderate impact on hospital admissions and healthcare costs,
as well as on health behaviors, the perceived quality of care, and
both patient and caregiver satisfaction. This systematic review
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the impact of the programs on the quality of life, medication
use, or utilization of outpatient care, mortality, or physical
and cognitive functional capacity.
This picture of how the current healthcare systems try to
cope with multimorbidity can be completed with the results of
several qualitative studies. While studies asked patients to
express their feelings about self-care and how they live with
multimorbidity, others asked healthcare professionals how they
manage or cannot manage patients with multimorbidity.
Asking patients for their opinion and feelings toward their
conditions revealed several barriers to self-care in the case of
multimorbidity. Among these barriers were physical limita-
tions, lack of knowledge on their conditions, financial issues,
and access to care. They also expressed the need for social and
emotional support and reported issues attributed to multiple
medications (e.g., managing and prioritizing medications or
adverse events of one medication impacting another condition
that is not the target of this medication) [56].
Primary care professionals (general practitioners and nurses)
acknowledged that there were tensions between proposing
quality care and accommodating patients’ agendas. Conditions
are managed in terms of priority in a system that works based
on the management of individual conditions. Dealing with co-
occurring somatic and psychic conditions was also considered
as problematic [57].
3.6. Immediate prospects for multimorbidity
Reductive approaches and measures based on the conse-
quences, rather than the causes, of multimorbidity have led to
an incorrect statement of the problem. First, the measures used,
though functional, do not lend themselves to either reprodu-
cible results or universal application. Indeed, the validity of the
definitions seems to depend on the outcome one wishes to
measure; a measure associated with the functional capacity
outcome will not be easy to use to study quality of life outcomes
[17]. Second, it has been shown that the definitions chosen
would not prove sufficient to characterize the experience
of patients, who beyond having multiple conditions, cite
individual social, financial, and organizational impacts
[14,21,26]. Moreover, from the perspective of improving the
quality of care – particularly primary care by general
practitioners – pay-for-performance (P4P) systems also create
problems when it comes to patients with multimorbidity. As
it now exists, P4P is based primarily on biomedical results,
which may have little meaning to the people receiving the care;
a more equitable payment system might adjust the payment
based on the severity of a patient’s health issues and thus on the
degree of multimorbidity.
The degree of multimorbidity is closely linked with the
individual’s level of deprivation. The fact that multimorbidity,
already quite prevalent, becomes even more so in poorer
populations is a major challenge. Improving the health status of
the general population would require tackling these social
inequalities, given the burden of chronic disease, since the
health of the most deprived contributes significantly to the totalburden of chronic conditions. The first step would require
reducing the burden caused by chronic disease and the burden
caused by social inequality simultaneously.
Beyond the difficulty of defining multimorbidity at the
individual patient level, the subject of multimorbidity seems to
be the symptom of a systemic, structural crisis in how we think
about health and disease on a number of levels. Multimorbidity
may be the prototype for a new way of defining disease, one
already begun by the complex integration of the following
realities: diseases as compared to syndromes, such as AIDS or
metabolic syndrome; the growing number of indirect measures
of a disease via diagnostic or prognostic markers; the
reorganization of healthcare systems in accordance with
efficiency or cost containment policies; and the desire for
personalized, patient-centered medicine. Hence we might
assume that the models already proposed for the individual
and collective management, at various levels, of a single
chronic condition – such as the Chronic Care Model – would
not be sufficient or totally suitable for addressing the reality of
multimorbidity. Moreover, it seems that patients are more and
more willing to be active partners in the whole care chain.
Building upon a consensus operational definition of
multimorbidity, we need more interventional research to
determine not only the most effective, but also the most
efficient and equitable forms of care and healthcare system
organization. As the Cochrane review pointed out, it will be
necessary to find a happy medium between creating new forms
of care and integrating care into the existing system so that its
development is sustainable. Beyond the biomedical aspect of
multimorbidity, efficient organization will no doubt require
recognition of patient expectations, including their need for
overall meaning in their particular situation. This could be
done by integrating different forms of therapeutic education
into healthcare systems. In addition, rather than increasing the
number of biomedical objectives in proportion to how many
comorbidities a person has, it might be more relevant to try to
build a common skills base aimed at the acquisition of
individual behaviors enabling the patient to adapt and manage
the different components of his condition and the constraints
engendered by his illness(es) [58,59].
4. Conclusion
Multimorbidity is a reality that, while distinct from, or
broader than, the concept of comorbidity, is difficult to define.
The different measures used to identify it are ambiguous, if
not contradictory. This leads to inappropriate responses at a
number of levels. Current healthcare systems do not seem well-
suited to the new medical and social reality that multimorbidity
represents. Our review of the literature underscores this
diversity and these contradictions.
Yet finding a single measure based on a consensus definition
of multimorbidity is no simple matter, because multimorbidity
is a complex combination of causes and effects, with many
related factors. The search for such a measure also reflects
different agendas, with some authors choosing some of the
elements of this combination over others, to reduce its
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not all actors seem to want a single measure. In any case, this
undertaking surely strips multimorbidity of its specific
irreducible features.
Converging toward consensus may require encompassing
diverse strategies, including an appropriate use of big data, a
collective reflection on the potential dimensions of multi-
morbidity to consider or the correct use of non-classical
analysis methods such as clustering methods. The biomedical
model may still provide valuable elements to start with while
not being sufficient to deal satisfyingly with the complexity of
multimorbidity.
Multidisciplinary research involving the patient, his family,
his disease, and the healthcare system is therefore needed. In
particular, it would be useful to determine whether there really
are specific multimorbid patient profiles, and if so, how many.
This research would be an opportunity to bring the focus back
to the patient and encourage the design of new therapeutic
education approaches with the patient. The operational
definition of multimorbidity could thus come from a
comparison of the common pathophysiological realities and
from the skills needed for multimorbid patient self-reliance.
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